Want to see IFF full AI Analyst Report?
Adjusted Operating EBITDA by Segment
Shows the profitability of each segment after removing non-recurring items, offering a clearer view of operational efficiency and segment performance.Since early‑2025 EBITDA contribution has materially re‑mixed: Taste, Health & Biosciences and Scent now account for the bulk of quarterly EBITDA while Nourish and Pharma Solutions drop out—consistent with IFF’s commodity carve‑outs and the Food Ingredients sale process. Taste’s strong Q1 2026 EBITDA reflects the volume, pricing and productivity wins management flagged, but watch Q2 margin pressure from energy/logistics and phased pricing pass‑through; the portfolio shift should improve long‑term margin resilience even as near‑term results remain sensitive to commodity cycles.
Date | Taste | Nourish | Health and Biosciences | Scent | Pharma Solutions | Global Expenses |
|---|---|---|---|---|---|---|
Jun 30, 2026 | $124.00M | $0.00 | $150.00M | $134.00M | $0.00 | $0.00 |
Mar 31, 2026 | $153.00M | $0.00 | $153.00M | $148.00M | $0.00 | $0.00 |
Dec 31, 2025 | $94.00M | $0.00 | $155.00M | $106.00M | $0.00 | $0.00 |
Sep 30, 2025 | $128.00M | $0.00 | $150.00M | $135.00M | $0.00 | $0.00 |
Jun 30, 2025 | $125.00M | $0.00 | $151.00M | $130.00M | $22.00M | $0.00 |
Mar 31, 2025 | $131.00M | $0.00 | $138.00M | $144.00M | $54.00M | $0.00 |
Dec 31, 2024 | $0.00 | $170.00M | $157.00M | $97.00M | $47.00M | $0.00 |
Sep 30, 2024 | $0.00 | $206.00M | $173.00M | $127.00M | $62.00M | $0.00 |
Jun 30, 2024 | $0.00 | $232.00M | $165.00M | $137.00M | $54.00M | $0.00 |
Mar 31, 2024 | $0.00 | $216.00M | $159.00M | $157.00M | $46.00M | $0.00 |